TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women, age 40-75 yrs, without any disease and need of medication.~* Born, raised and currently living at low altitude (\<800m).~* Written informed consent.~* Kyrgyz ethnicity~Exclusion Criteria:~* Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure.~* Any condition that may interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day or \>20 pack-years with active smoking during the last 10 years), regular use of alcohol.~* Allergy to acetazolamide and other sulfonamides.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- ACETAZOLAMIDE oral capsule (Type: ACTIVE_COMPARATOR): Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
- PLACEBO oral capsule (Type: PLACEBO_COMPARATOR): Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Male and female patients with type 2 Diabetes Mellitus who have never been treated with Trazenta tablets / Linagliptin (monotherapy) before enrollment. (Trazenta group)~* Patients with type 2 Diabetes Mellitus starting any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug (OAD)) except Trazenta tablets. (OAD group)~Exclusion criteria:~None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral antidiabetic drug (OAD) (Type: None): None
- Trazenta (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects who are ≥18 years of age on the day of signing informed consent,~* have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,~* have ≥6 swollen joints (from a 66-joint count) and~  ≥8 tender joints (from a 68-joint count) at Screening and at Baseline,~* Screening serum c-reactive protein ≥ 0.7 x upper limit of laboratory normal range (ULN),~* have shown an inadequate response in terms of either lack of efficacy or toxicity to MTX,~* have agreed to be washed out from MTX for a period of at least 4 weeks before or during the Screening period.~Exclusion Criteria:~* current therapy with any non-biological disease modifying anti-rheumatic drug (DMARD), with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to Screening,~* current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs: administered in a single clinical study setting, and; more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), and; where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,~* previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
- GLPG0634 50 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
- GLPG0634 100 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
- GLPG0634 200 mg QD (Type: EXPERIMENTAL): Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 75 years, Male and female patients;~* Type 2 diabetes mellitus;~* Control the blood glucose level only with diet and exercise in last 8 weeks;~* Did not receive regular long-term medication of oral hypoglycemic drugs or insulin within 1 year prior to informed consent;~* HbA1c in the range of ≥7.5 to ≤11.0% at screening;~* FPG \< 15 mmol/L at screening;~* BMI (Body Mass Index) in the range of ≥ 18.0 kg/m² to ≤ 35.0 kg/m² at screening.~Exclusion Criteria:~* Diabetic ketoacidosis, hyperglycemia hypertonic state, serious complications of diabetes, myocardial infarction, stroke within 6 months prior to informed consent;~* History of severe endocrine disease, uncured cancer, acute pancreatitis prior to informed consent;~* Current hemoglobinopathy, uncontrolled hypertension, serious nephropathy or hepatopathy prior to informed consent;~* Serious gastrointestinal disease within 2 weeks prior to informed consent;~* Serious infection, trauma and surgery within 3 months prior to informed consent;~* History of treatment with Dipeptidyl-Peptidase 4 (DPP-4) inhibitor, Glucose-dependent insulinotropic polypeptide (GIP) or Glucagon-like peptide-1 (GLP-1) receptor agonist;~* Treatment with drugs that affect glucose metabolism within 8 weeks prior to informed consent;~* Hemoglobin (HGB) \< 10.0 g/dL(100 g/L);~* Alcohol abuse within 6 months or drug abuse history within 5 years prior to informed consent;~* Active infectious diseases;~* Participation in another trial with an investigational drug or instrument within 3 months prior to informed consent;~* Women who are nursing or pregnant, or subjects with birth plans;~* Contraindication for metformin;~* Other protocol-defined inclusion/exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HSK7653 10 mg (Type: EXPERIMENTAL): None
- HSK7653 25 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged \>= 6 months to 12 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including but not limited to one or more of the following:~   * fever at the time of evaluation (axillary temperature 37.5° C by digital thermometer)~  * report of fever within the last two days~  * profound anemia (conjunctival or palmar pallor)~  * headache~  * body aches~  * abdominal pain~  * decreased intake of food or fluids~  * weakness~2. Positive malaria smear for P. falciparum mono-infection~3. Parasite density of 2,000-200,000/microliter or \< 10%~4. Willingness to remain at the Health Centre under continuous observation until the resolution of the infection~5. Parental consent for each participant, and child assent for children older than 5 years~Exclusion Criteria:~1. Signs of severe malaria: One or more of the following:~   * hemoglobin \< 5 g/dl~  * parasitemia \> 10%~  * prostration \* as indicated by inability to drink or breastfeed~  * respiratory distress (deep Kussmaul respirations)~  * bleeding~  * recent seizures\*, coma\* or mental obtundation\* (Blantyre coma score less than 5)~  * persistent vomiting\*~2. Presence of a severe disease~3. Presence of a febrile condition caused by diseases other than malaria~4. Known allergy or history of adverse reaction to sulfadoxine/pyrimethamine (SP), sulfa drugs or chloroquine~5. Chronic medication with an antifolate drug~6. Enrollment in this clinical study in the past 28 days \*Each of these symptoms or signs is considered a danger sign.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pediatric Intermed: A New Clinical Decision Making Tool

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of IBD (Crohn's or Ulcerative Colitis)~* fluency in English or French~* between the ages of 8 and 17~* residing in the CHEO catchment area.~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Children and youth with IBD (Type: None): Children/youth (ages 8-17) with confirmed diagnoses of IBD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who are 18 years of age or older~* Patients who are scheduled for an elective cemented or uncemented total unilateral knee replacement or total unilateral hip replacement, under general or spinal anesthesia that does not include use of an intrathecal opioid~* Post-surgical patients who have been admitted to the PACU and are expected to remain hospitalized and to have acute post-operative pain requiring parenteral opioids for at least 48 hours after surgery~Exclusion Criteria:~* Patients who have undergone a replacement of the same knee or hip~* Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet)~* Patients with an allergy or hypersensitivity to opioids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sufentanil NanoTab PCA System/15 mcg (Type: EXPERIMENTAL): None
- Placebo Sufentanil NanoTab PCA System (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females of age ≥ 18 years.~2. Individuals who had given written consent.~3. Individuals in good health and available for all the visits scheduled in the study.~Exclusion Criteria:~1. Pregnancy or unwillingness to practice acceptable contraception.~2. A history of Rabies vaccination.~3. History of allergy to egg protein.~4. Known hypersensitivity to neomycin, tetracycline, amphotericin-B or any other vaccine component.~5. A significant acute or chronic infectious disease or use of antibiotics that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment.~6. Body temperature ≥38.0°C (≥ 100.4°F) within 3 days of study vaccination.~7. Treatment with an anti-malarial drug, up to two months prior to the study.~8. Individuals who received any other vaccines within 28 days prior to enrollment.~9. Subjects who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks.~10. Any planned surgery during the study period.~11. Subjects who have cancer disorders excluding nonmelanotic skin cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A-Zagreb (Type: ACTIVE_COMPARATOR): Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
- Group B-Essen (Type: ACTIVE_COMPARATOR): Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of RF Microneedle on Photoaging Skin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult more than 19 years old~* Melasma clinically diagnosed by three dermatologists~Exclusion Criteria:~* Aesthetic medical procedures in three months prior to the study~* Use of topical depigmenting agents in three months prior to the study~* Pregnant or lactating

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional therapy with RF microneedle (Type: EXPERIMENTAL): Half face Oral tranexamic acid combined with triple combination cream with RF microneedle
- Conventional therapy (Type: ACTIVE_COMPARATOR): Half face Oral tranexamic acid combined with triple combination cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Expected minimum hospital stay of 5 days~* Expected ≥5 day course of intravenous (IV) ceftriaxone alone or in combination with a macrolide~* Clinical diagnosis of moderate to severe lower respiratory tract infection consisting of signs and symptoms of a lower respiratory tract infection and Pneumonia Severity Index (PSI/PORT) score for CAP of 90-130, inclusive. Evidence of a new or progressive infiltrate on chest x-ray is recommended.~Exclusion Criteria:~* Presence of a diarrheal illness within 72 hours prior to randomization~* Current treatment for CDAD or ongoing active CDI, as evidenced by clinical signs of diarrhea along with the presence of toxin A and/or B (or their respective genes, tcdA and/or tcdB) of C. difficile in the stool~* Number of previous CDAD episodes \>1 within 12 weeks of randomization and no C. difficile infection (CDI) within 4 weeks of randomization~* Use of antibiotics within 1 month of start of study drug except for the current illness.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYN-004 (Type: EXPERIMENTAL): SYN-004 150 mg
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CML-CP patients achieving an optimal response to imatinib treatment with Grade 1 or 2 non-hematologic adverse events persisting for at least 2 months or recurring at least 3 times in the preceding 12 months, despite best supportive care~* Men and women with Chronic Myeloid Leukemia- Chronic Phase (CML-CP) Ph+ ≥ age 18~* Daily Eastern Co-Operative Group (ECOG) performance status = 0 - 2~* Patient willing and able to give informed consent~* Life expectancy \> 6 months~* Adequate renal function~* Adequate hepatic function~Exclusion Criteria:~* Patients who are pregnant or breast feeding~* Men whose partner is unwilling to avoid pregnancy.~* Previous treatment with any other tyrosine-kinase inhibitor (TKI), except for imatinib~* Current grade 3 or 4 imatinib related adverse event~* Prior documented T315I mutation~* Prior diagnosis of accelerated phase or blast crisis CML~* Previous loss of complete hematologic response (CHR) or major cytogenetic response (MCyR) on imatinib~* Concurrent medical condition of uncontrolled infection, cardiovascular diseases of cardiac failure, congenital long QT syndrome, ventricular arrhythmias, prolonged QT interval, second or third degree heart block, uncontrolled angina, myocardial infarction (MI) in the last 6 months, uncontrolled hypertension, pulmonary arterial hypertension, pleural or pericardial effusions, or history of bleeding disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (100 mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Major inclusion criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2~* Pathologically confirmed relapsed/refractory DLBCL~* Subjects must have ≥1 measurable disease site on CT scan (≥ 1.5 cm in longest dimension).~* Adequate hepatic and renal function:~  * AST or ALT ≤2.5 x ULN~ * Serum Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥60 mL/min/1.73~ * Bilirubin ≤1.5 x ULN~* Adequate hematologic function:~  * ANC \>1,000 cells/mm3~ * Platelets ≥75,000 cells/mm3~ * Hemoglobin ≥8.0 g/dL~ * Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be ≤1.5 x the upper limit of the normal range (ULN)~* Must be registered into the Revlimid REMS™program and be willing to comply with the requirements of Revlimid REMS™.~Major Exclusion Criteria:~* Known central nervous system lymphoma~* Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks~* Radio- or toxin-immunoconjugates within 10 weeks~* Prior allogenetic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Dose Level 1 (Type: EXPERIMENTAL): Ibrutinib 560 mg PO + DA-EPOCH-R
- Part 1: Dose Level 2 (Type: EXPERIMENTAL): Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
- Part 1: Dose Level 3 (Type: EXPERIMENTAL): Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
- Part 1: Dose Level 4 (Type: EXPERIMENTAL): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
- Part 2: RP2D (Type: EXPERIMENTAL): Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with CTEPH or PAH in NYHA class II or III~Exclusion Criteria:~* Patients with PDE 5 inhibitor or prostacycline pretreatment, relevant pulmonary diseases, relevant cardiac diseases, severe coagulation disorders, moderate to severe hepatic or renal insufficiency, pregnancy, hypotension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete